Navigation Links
FDA approves drug for rare liver disease

Hereditary tyrosinemia type 1( HT-1) is a genetic metabolic disorder that causes progressive liver failure and liver cancer in young children. It's a very rare disease.// It is not among the metabolic diseases that all newborns are tested for at birth, so often infants die undiagnosed. This is an absolutely fatal disease until now.

Children born with such a very rare but very lethal liver disease have won the first drug that promises to help them live years longer. The drug, named Orfadin, amazingly is a failed weed killer that Swedish scientists discovered could fight a disease called hereditary tyrosinemia.

"This is a real breakthrough drug," said Dr. Marlene Haffner of the U.S. Food and Drug Administration. She said scientists once referred to the drug as "Lazarene, because these kids were so sick and then they were well."

For babies who are diagnosed, the only treatment is a special low-protein diet. Orfadin may significantly improve those dismal statistics. It works by blocking formation of the liver-destroying toxins. The drug's cost depends on the dose, which varies with the child's size: $12,000 a year for an infant, up to $60,000 a year for an older child.
'"/>




Page: 1

Related medicine news :

1. FDA approves new device to treat womens bleeding disorder
2. FDA approves surgical gel
3. FDA approves first pocket-sized EKG machine
4. FDA approves Watson Pharmaceuticals Oxytrol patch
5. Indian Health Ministry approves sale of Emergency contraceptives as over the counter drug
6. Madras High Court Disapproves of Comparative Advertisements
7. FDA approves Phase 0 trial which tests experimental drugs on humans
8. FDA approves CLARINEX-D 12 HOUR for seasonal allergic rhinitis
9. Study disapproves a new Asthma inhaler
10. GMC Disapproves Internet Doctor
11. Laboratory Testing Can Identify Risk of Pre-Term Labor and Delivery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: